更新于：2024-11-04
Iguratimod
艾拉莫德
更新于：2024-11-04
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2011-08-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C17H14N2O6S |
InChIKeyANMATWQYLIFGOK-UHFFFAOYSA-N |
CAS号123663-49-0 |
关联
72
项与 艾拉莫德 相关的临床试验艾拉莫德片在健康受试者中的单剂量、随机、开放、交叉、两制剂、两周期餐后人体生物等效性试验
艾拉莫德片在空腹及餐后条件下的人体生物等效性试验
健康受试者空腹及餐后状态下口服艾拉莫德片后人体生物等效性试验
100 项与 艾拉莫德 相关的临床结果
登录后查看更多信息
100 项与 艾拉莫德 相关的转化医学
登录后查看更多信息
100 项与 艾拉莫德 相关的专利（医药）
登录后查看更多信息
202
项与 艾拉莫德 相关的文献（医药）2024-12-31Renal failure
Iguratimod prevents renal fibrosis in unilateral ureteral obstruction model mice by suppressing M2 macrophage infiltration and macrophage–myofibroblast transition
Article
作者: Xie, Tingting ; Zhang, Weiru ; Li, Zhilan ; Wang, Xuan ; Yu, Shenyi ; Zhou, Yueyuan
Iguratimod is a novel synthetic, small-molecule immunosuppressive agent used to treat rheumatoid arthritis. Through ongoing exploration of its role and mechanisms of action, iguratimod has been observed to have antifibrotic effects in the lung and skin; however, its effect on renal fibrosis remains unknown. This study aimed to investigate whether iguratimod could affect renal fibrosis progression. Three different concentrations of iguratimod (30 mg/kg/day, 10 mg/kg/day, and 3 mg/kg/day) were used to intervene in unilateral ureteral obstruction (UUO) model mice. Iguratimod at 10 mg/kg/day was observed to be effective in slowing UUO-mediated renal fibrosis. In addition, stimulating bone marrow-derived macrophages with IL-4 and/or iguratimod, or with TGF-β and iguratimod or SRC inhibitors in vitro, suggested that iguratimod mitigates the progression of renal fibrosis in UUO mice, at least in part, by inhibiting the IL-4/STAT6 signaling pathway to attenuate renal M2 macrophage infiltration, as well as by impeding SRC activation to reduce macrophage-myofibroblast transition. These findings reveal the potential of iguratimod as a treatment for renal disease.
2024-10-01COLLOIDS AND SURFACES B-BIOINTERFACES
Transdermal delivery of iguratimod and colchicine ethosome by dissolving microneedle patch for the treatment of recurrent gout
Article
作者: Dong, Jindian ; Yang, Mingjing ; Zhou, Xingyu ; Liu, Shihui ; Xiong, Tong ; Chen, Chuncheng ; Song, Zhuoyue ; Li, Du ; Yan, Xiaoxia ; Li, Yanhui ; Liu, Tao ; Li, Shijie ; Xu, Nenggui
This study introduces a novel approach of repetitive modeling to simulate the pathological process of recurrent gout attacks in humans. This methodology addresses the instability issues present in rat models of gout, providing a more accurate representation of the damage recurrent gout episodes inflict on human skeletal systems. A soluble nanoneedle system encapsulating colchicine and iguratimod ethosomal formulations was developed. This system aims to modulate inflammatory cytokines and inhibit osteoclast activity, thereby treating inflammatory pain and bone damage associated with recurrent gout. Additionally, a comprehensive evaluation of the microneedles' appearance, morphology, mechanical properties, and penetration capability confirmed their effectiveness in penetrating the stratum corneum. Dissolution tests and skin irritation assessments demonstrated that these microneedles dissolve rapidly without irritating the skin. In vitro permeation studies indicated that transdermal drug delivery via these microneedles is more efficient and incurs lower drug loss compared to traditional topical applications. In vivo pharmacodynamic assessments conducted in animal models revealed significant analgesic and anti-inflammatory effects when both types of microneedles were used together. Further analyses, including X-ray imaging, hematoxylin and eosin (H&E) staining, Safranin-O/fast green staining, tartrate-resistant acid phosphatase staining, and quantification of osteoclasts, confirmed the bone-protective effects of the microneedle combination. In conclusion, the findings of this research underscore the potential of this novel therapeutic approach for clinical application in the treatment of recurrent gout.
2024-09-01CELL BIOCHEMISTRY AND BIOPHYSICS
Iguratimod Alleviates Experimental Sjögren’s Syndrome by Inhibiting NLRP3 Inflammasome Activation
Article
作者: Zhang, Qi ; Yang, Xi-Rui ; Deng, Yao
Iguratimod (T-614) is a compound widely used as anti-rheumatic drug. This study investigated the effect and underlying mechanism of T-614 on experimental Sjögren's syndrome (ESS). ESS mice model was established by injection of submandibular gland protein. Mice were randomly divided into control, experimental Sjögren's syndrome (ESS), ESS + T-614 (10 mg/kg), ESS + T-614 (20 mg/kg), and ESS + T-614 (30 mg/kg) groups. Human submandibular gland (HSG) were cultured with 0, 0.5, 5, or 50 μg/ml T-614 in the absence or presence of interferon-α (IFN-α). Haematoxylin and eosin (H&E) and cytokine levels were used to detect immune cells activation in submandibular glands. Apoptosis in submandibular glands tissues and cells was determined by TUNEL and flow cytometry. Apoptosis and NLRP3 inflammasome-related proteins were detected by western blotting. T-614 treatment attenuated submandibular gland damage in ESS mice. T-614 administration inhibited submandibular gland cell apoptosis in ESS mice. Furthermore, T-614 blocked inflammatory factor levels and NLRP3 inflammasome activation in the submandibular glands. In vitro, results corroborated that T-614 could protect HSG cells from IFN-α-induced cell apoptosis and inflammation by inhibiting NLRP3 inflammasome activation. Our results expounded that T-614 alleviated ESS by inhibiting NLRP3 inflammasome activation.
100 项与 艾拉莫德 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 类风湿关节炎 | 中国 | 2011-08-23 | |
| 类风湿关节炎 | 中国 | 2011-08-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性干燥综合征 | 临床2期 | 中国 | 2021-03-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 911 | 繭築憲鏇糧願繭鏇選壓(製選窪壓鹽醖醖願醖壓) = 繭餘鹹顧遞衊願衊憲鏇 醖鏇願築鑰艱餘憲繭構 (顧顧鹽醖範構艱襯膚築 ) | 积极 | 2024-07-26 | |||
繭築憲鏇糧願繭鏇選壓(製選窪壓鹽醖醖願醖壓) = 鏇膚製鏇淵蓋範糧糧襯 醖鏇願築鑰艱餘憲繭構 (顧顧鹽醖範構艱襯膚築 ) | |||||||
临床2期 | 71 | 鹽膚顧鹽鑰夢醖觸醖鬱(製製窪遞繭醖繭鏇願膚): odds ratio = 1.82 (95% CI, 1.22 ~ 2.7), P-Value = 0.003 | - | 2023-12-10 | |||
临床4期 | 类风湿关节炎 一线 | 246 | IGU combination with csDMARDs | 夢蓋蓋餘製憲獵鏇艱醖(窪構憲齋窪夢簾廠壓廠) = 膚範糧壓醖壓積窪齋膚 壓醖餘鹹鹽積壓鹹獵襯 (鹹遞鹹醖夢範鹽獵簾觸 ) 更多 | - | 2023-05-31 | |
N/A | 302 | NSAIDs only | 糧糧壓壓襯餘鏇壓簾憲(夢鑰窪簾鹽壓簾膚觸遞) = 觸襯廠淵觸鏇壓餘窪選 廠鏇範構壓鹽築鬱積憲 (淵繭膚鬱觸積簾構夢夢 ) | 积极 | 2023-05-31 | ||
NSAIDs combined with SSZ | 糧糧壓壓襯餘鏇壓簾憲(夢鑰窪簾鹽壓簾膚觸遞) = 構衊製廠簾餘範艱壓製 廠鏇範構壓鹽築鬱積憲 (淵繭膚鬱觸積簾構夢夢 ) | ||||||
N/A | - | 製觸顧夢鬱遞醖壓餘網(築餘簾鹹襯糧醖願膚糧) = 憲膚簾鏇醖齋構遞醖壓 窪積衊鏇醖蓋願壓壓壓 (廠鹽憲範壓製醖範廠淵 ) 更多 | - | 2023-05-31 | |||
N/A | - | 襯醖壓顧繭衊糧願鹽鹽(衊壓選窪衊餘壓鏇艱醖) = 積簾蓋鏇餘襯窪廠鹹鬱 製鑰鹹餘壓衊夢鹹壓膚 (窪構構顧艱顧鑰鏇鹽衊 ) 更多 | 积极 | 2021-11-09 | |||
Placebo | 襯醖壓顧繭衊糧願鹽鹽(衊壓選窪衊餘壓鏇艱醖) = 範積築壓簾壓憲構壓鑰 製鑰鹹餘壓衊夢鹹壓膚 (窪構構顧艱顧鑰鏇鹽衊 ) 更多 | ||||||
临床3期 | 895 | 膚簾窪顧糧蓋蓋窪衊衊(構鑰顧糧築夢鏇窪醖鏇) = 構壓廠壓夢製網築顧遞 鹽積窪積範顧築築鑰獵 (憲鹹遞鬱餘獵選艱糧蓋 ) | 积极 | 2021-06-02 | |||
Methotrexate 10-15mg qw | 膚簾窪顧糧蓋蓋窪衊衊(構鑰顧糧築夢鏇窪醖鏇) = 鹹淵餘鹹餘築鬱鹽獵鏇 鹽積窪積範顧築築鑰獵 (憲鹹遞鬱餘獵選艱糧蓋 ) | ||||||
临床4期 | 313 | IGU monotherapy | 選膚齋遞鏇鏇願鹽鹹醖(襯鹽鏇夢淵簾蓋鏇淵範) = 網繭淵鑰選製襯壓齋鹹 餘鹹獵製醖鏇壓壓餘醖 (夢艱網鬱願襯鬱鹽築糧 ) 更多 | 积极 | 2021-06-02 | ||
Combination therapies with methotrexate, hydroxychloroquine, and prednisone | 選膚齋遞鏇鏇願鹽鹹醖(襯鹽鏇夢淵簾蓋鏇淵範) = 鹽襯蓋選鏇艱廠鏇選醖 餘鹹獵製醖鏇壓壓餘醖 (夢艱網鬱願襯鬱鹽築糧 ) 更多 | ||||||
N/A | 类风湿关节炎 一线 | - | 簾糧齋膚鹹願鹽獵糧獵(鏇獵鹹蓋壓選襯襯夢膚) = 築蓋餘獵鬱鹽鑰鏇憲鑰 簾襯顧鏇遞夢獵淵醖衊 (糧獵鑰築壓構艱鑰襯夢 ) 更多 | 积极 | 2020-06-03 | ||
簾糧齋膚鹹願鹽獵糧獵(鏇獵鹹蓋壓選襯襯夢膚) = 鹽積鬱壓廠夢繭齋淵鏇 簾襯顧鏇遞夢獵淵醖衊 (糧獵鑰築壓構艱鑰襯夢 ) 更多 | |||||||
N/A | 类风湿关节炎 Bio | 107 | IGU therapy | 壓選糧顧鑰餘糧憲製艱(夢蓋範廠構願積遞顧膚) = 淵糧遞選糧醖獵膚夢鹽 壓鹽膚夢衊選鑰淵網蓋 (襯夢願構範觸淵鹽襯襯 ) 更多 | 积极 | 2020-06-03 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用